Meral Beksaç

2000–2026 年に発表

別表記
Meral Beksac
124
論文数
27,248
被引用数
69
h 指数
111
i10 指数

被引用数

Meral Beksaç の年別被引用数1948 年: 被引用 1 件1988 年: 被引用 1 件1989 年: 被引用 1 件1990 年: 被引用 1 件1993 年: 被引用 1 件1994 年: 被引用 1 件2000 年: 被引用 1 件2002 年: 被引用 2 件2003 年: 被引用 3 件2004 年: 被引用 6 件2005 年: 被引用 10 件2006 年: 被引用 13 件2007 年: 被引用 23 件2008 年: 被引用 45 件2009 年: 被引用 45 件2010 年: 被引用 56 件2011 年: 被引用 84 件2012 年: 被引用 127 件2013 年: 被引用 150 件2014 年: 被引用 168 件2015 年: 被引用 163 件2016 年: 被引用 232 件2017 年: 被引用 237 件2018 年: 被引用 188 件2019 年: 被引用 827 件2020 年: 被引用 914 件2021 年: 被引用 1,034 件2022 年: 被引用 772 件2023 年: 被引用 541 件2024 年: 被引用 1,049 件2025 年: 被引用 501 件2026 年: 被引用 15 件1949〜1987 年は被引用が無いため表示していません1991〜1992 年は被引用が無いため表示していません1995〜1999 年は被引用が無いため表示していません2001 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,110 件、この内訳の 21.5%中国: 引用元論文 667 件、この内訳の 6.8%イタリア: 引用元論文 607 件、この内訳の 6.2%ドイツ: 引用元論文 602 件、この内訳の 6.1%イギリス: 引用元論文 562 件、この内訳の 5.7%フランス: 引用元論文 540 件、この内訳の 5.5%スペイン: 引用元論文 533 件、この内訳の 5.4%オランダ: 引用元論文 345 件、この内訳の 3.5%カナダ: 引用元論文 329 件、この内訳の 3.3%ギリシャ: 引用元論文 318 件、この内訳の 3.2%オーストラリア: 引用元論文 271 件、この内訳の 2.8%ベルギー: 引用元論文 216 件、この内訳の 2.2%
0%21.5%その他 27.8%

分野

  • Medicine75%
  • Biochemistry, Genetics and Molecular Biology17.2%
  • Immunology and Microbiology3.4%
  • Computer Science2%
  • Engineering0.5%
  • Social Sciences0.3%
  • その他1.6%

トピック

  • Multiple Myeloma Research and Treatments21.3%
  • Protein Degradation and Inhibitors9.1%
  • Peptidase Inhibition and Analysis5.5%
  • CAR-T cell therapy research3.1%
  • Cancer Treatment and Pharmacology3.1%
  • Amyloidosis: Diagnosis, Treatment, Outcomes2.7%
  • その他55.2%

共著者

全論文

検索で開く
  1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert A. Kyle, Kenneth C. Anderson, Brian G.M. Durie, Jesús F. San Miguel - The Lancet Oncology 2014 被引用: 4,869

  2. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez‐Otero, Joan Bladé, Philippe Moreau - New England Journal of Medicine 2023 被引用: 515

  3. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kevin Song, Timon Hansen, Salomon Manier, Wilfried Roeloffzen, Krzysztof Jamroziak, Fiona Kwok, Chihiro Shimazaki, Jin Seok Kim, Edvan Crusoé, Tahamtan Ahmadi, NamPhuong Tran, Xiang Qin, Sandra Y. Vasey, Brenda Tromp, Jordan M. Schecter, Brendan M. Weiss, Sen Hong Zhuang, Jessica Vermeulen, Giampaolo Merlini, Raymond L. Comenzo - New England Journal of Medicine 2021 被引用: 668

  4. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 178

  5. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 被引用: 1,513

  6. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey Shang-Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Kathryn P. Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C. Anderson, Simon J. Harrison, Wojciech Janowski, Ian Kerridge, Andrew Spencer, Michel Delforge, Karel Fostier, Philip Vlummens, Ka Lung Wu, Richard LeBlanc, Michel Pavic, Michaël Sébag, Roman Hájek, Vladimír Maisnar, Luděk Pour, Henrik Gregersen, Lotfi Benbouker, Denis Caillot, Martine Escoffre‐Barbe, Thierry Façon, Laurent Frenzel, Cyrille Hulin, Lionel Karlin, Brigitte Kolb, Brigitte Pegourié, Aurore Perrot, Mourad Tiab, Laure Vincent, Dietger Niederwieser, Αchilles Anagnostopoulos, Sosana Delimpasi, Marie‐Christine Kyrtsonis, Anargyros Symeonidis, Árpád Illés, Gábor Mikala, Zsolt Nagy, Sara Bringen, Paolo Corradini, Fabio Ciceri, Roberto M. Lemoli, Anna Marina Liberati, Chiara Nozzoli, Renato Zambello, Shinsuke Iida, Takashi Ikeda, Satoshi Iyama, Morio Matsumoto, Chihiro Shimazaki, Kazutaka Sunami, Kenshi Suzuki, Michihiro Uchiyama, Youngil Koh, Kihyun Kım, Jae Hoon Lee, Chang‐Ki Min, Hillary Blacklock, Hugh J. B. Goodman, Annette Neylon, David Simpson, Sebastian Grosicki, Artur Jurczyszyn ほか 30 名 - The Lancet 2019 被引用: 636

  7. International uniform response criteria for multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , on behalf of the International Myeloma Working Group - Leukemia 2006 被引用: 2,639

  8. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Mario Boccadoro, Michèle Cavo, Javier de la Rubia Comos, Sosana Delimpasi, Meletios Α. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Façon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hájek, Güner Hayri Özsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Eirini Katodritou, Stefan Knop, Marie‐Christine Kyrtsonis, Juan José Lahuerta, Xavier Leleu, Carmen Martínez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique C. Minnema, Philippe Moreau, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlıvan, Luděk Pour, Henk Roerdink, Laura Rosinol Dacsh, Hans Salwender, Pieter Sonneveld, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tülin Tuğlular, Ali Ünal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman - The Lancet Oncology 2021 被引用: 327

  9. Extramedullary disease in multiple myeloma: a systematic literature review

    著者: , , , , , , , , , , - Blood Cancer Journal 2022 被引用: 278

  10. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 151

  11. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 1,320

  12. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Achilleas Anagnostopoulos, Larry D. Anderson, Pekka Anttila, Carla Araujo, Carlos Arce‐Lara, Yıldız Aydın, Supratik Basu, Ramakrishna Battini, Thaddeus Beeker, Lotfi Benboubker, Dina Ben‐Yehuda, Joan Bladé, Igor Wolfgang Blau, Ralph V. Boccia, Lillian Burke, Peter D. Byeff, Nicola Cascavilla, Michèle Cavo, Andrew Chantry, Yen Charles, Arvind Chaudhry, Alessandro Corso, Mark Coyne, Felipe de Arriba, Sosana Delimpasi, Pierre Desjardins, Binod Dhakal, Paolo Di Bartolomeo, Francesco Di Raimondo, Jan Dürig, Monika Engelhardt, Martine Escoffre‐Barbe, Graça Esteves, Max Flogegård, Nashat Gabrail, Barbara Gamberi, Mitchell Garrison, Julie Gay, Heinz Gisslinger, Hartmut Goldschmidt, Cristina Gonçalves, Laurent Gressot, Sebastian Grosicki, Wahid T. Hanna, Patrick Hayden, Maria Manuela Henriques Bernardo, Róbert Hermann, Viran Holden, Kirsti Honkalehto, Marianne Huben, John Huffman, Hannah Hunter, Marek Hus, Madan Jagasia, Sundar Jagganath, Murali Janakiram, Ishmael Jaiyesimi, Matthew Jenner, Cristina João, Peter Johnson, Artur Jurcyszyn, Sevgi Kalayoğlu Beşışık, Suman Kambhampati, Abraham S. Kanate, Ìhsan Karadoǧan, Ali Khojasteh, Dean Kirkel, Mieczysław Komarnicki, Maria‐Theresa Krauth, Phillip Kuriakose ほか 65 名 - The Lancet Oncology 2019 被引用: 385

  13. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 243

  14. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 被引用: 268

  15. HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA

    著者: , , , , , , , , , , , , , - Journal of Hematology & Oncology 2021 被引用: 176

  16. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

    著者: , , , , , , , , , , , , , , , , - The Lancet Oncology 2022 被引用: 114

  17. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Javier de la Rubia, Peter Gimsing, Sagar Lonial, Jonathan L. Kaufman, Enrique M. Ocio, Ljupco Veskovski, Sang Kyun Sohn, Ming-Chung Wang, Jae Hoon Lee, Hermann Einsele, Monika Sopala, Claudia Corrado, B. Bengoudifa, Florence Binlich, Paul G. Richardson - The Lancet Oncology 2014 被引用: 788

  18. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Annemiek Broijl, Rossella Troia, Anna Pascarella, Giulia Benevolo, Mark‐David Levin, Gerard M.J. Bos, Heinz Ludwig, Sara Aquino, Anna Morelli, Ka Lung Wu, Rinske Boersma, Roman Hájek, Marc Durian, Peter A. von dem Borne, Tommaso Caravita di Toritto, Thilo Zander, Christoph Driessen, Giorgina Specchia, Anders Waage, Peter Gimsing, Ulf‐Henrik Mellqvist, Marinus van Marwijk Kooy, Monique C. Minnema, Caroline M.P.W. Mandigers, Anna Maria Cafro, Angelo Palmas, Susanna Carvalho, Andrew Spencer, Mario Boccadoro, Pieter Sonneveld - The Lancet Haematology 2020 被引用: 384

  19. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 160

  20. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 120

  21. Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Saad Z. Usmani, Karin Vanderkerken, David H. Vesole, Anders Waage, Sonja Zweegman, Paul G. Richardson, Joan Bladé - British Journal of Haematology 2021 被引用: 174

  22. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 121

  23. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ashraf Badros, Philippe Moreau, K Kim, P R Otero, J H Lee, Chaim Shustik, Daniel D. Waller, Wee Joo Chng, Shuji Ozaki, J-J Lee, Javier de la Rubia, Hyeon‐Seok Eom, Laura Rosiñol, Juan José Lahuerta, Anna Sureda, Jin Seok Kim, B G M Durie - Leukemia 2017 被引用: 354

  24. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma

    著者: , , , , , , , , , , , , , , , - Molecular Cancer 2021 被引用: 74